| Literature DB >> 28477547 |
Sayuri Ishiwata1, Kotaro Hattori2, Daimei Sasayama3, Toshiya Teraishi3, Tomoko Miyakawa4, Yuuki Yokota4, Ryo Matsumura4, Fuyuko Yoshida3, Toru Nishikawa5, Hiroshi Kunugi6.
Abstract
G72 is a modulator of D-amino acid oxidase, the enzyme that degrades D-serine, an amino acid that plays a critical role in glutamate neurotransmission, and has been implicated in psychiatric disorders. The aim of this study was to examine whether plasma or cerebrospinal fluid (CSF) G72 protein levels were altered in either schizophrenia or major depressive disorder (MDD) and whether any correlation between G72 levels and disease severity existed. Initially, 27 schizophrenic patients, 26 MDD patients, and 27 healthy controls matched for age, sex, and ethnicity were enrolled. Compared to those of controls, plasma or CSF G72 levels were not significantly different in patients with schizophrenia or MDD. Although we found a significant positive correlation between plasma G72 levels and a positive symptoms score on the positive and negative syndrome scale (PANSS), this was not replicated in the second study (40 schizophrenic patients). CSF G72 levels showed no significant correlation with PANSS scores. In MDD, neither plasma nor CSF G72 levels correlated significantly with depression severity. Since severity of our patients were relatively mild, further investigations in a large number of subjects including drug-free patients, younger patients, and more severely affected patients are warranted.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28477547 DOI: 10.1016/j.psychres.2017.04.060
Source DB: PubMed Journal: Psychiatry Res ISSN: 0165-1781 Impact factor: 3.222